T Cell Reactivity Against Mycolyl Transferase Antigen 85 of M. Tuberculosis in HIV-TB Coinfected Subjects and in AIDS Patients Suffering from Tuberculosis and Nontuberculous Mycobacterial Infections

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2010 Oct 12

PMID 20936150

Citations 8

Authors

Pascal Launois

Annie Drowart

Eliane Bourreau

Pierre Couppie

Claire-Michele Farber

Jean-Paul Van Vooren

Kris Huygen

Affiliations

Soon will be listed here.

Abstract

The mycolyl transferase antigen 85 complex is a major secreted protein family from mycobacterial culture filtrate, demonstrating powerful T cell stimulatory properties in most HIV-negative, tuberculin-positive volunteers with latent M.tuberculosis infection and only weak responses in HIV-negative tuberculosis patients. Here, we have analyzed T cell reactivity against PPD and Ag85 in HIV-infected individuals, without or with clinical symptoms of tuberculosis, and in AIDS patients with disease caused by nontuberculous mycobacteria. Whereas responses to PPD were not significantly different in HIV-negative and HIV-positive tuberculin-positive volunteers, responses to Ag85 were significantly decreased in the HIV-positive (CDC-A and CDC-B) group. Tuberculosis patients demonstrated low T cell reactivity against Ag85, irrespective of HIV infection, and finally AIDS patients suffering from NTM infections were completely nonreactive to Ag85. A one-year follow-up of twelve HIV-positive tuberculin-positive individuals indicated a decreased reactivity against Ag85 in patients developing clinical tuberculosis, highlighting the protective potential of this antigen.

Citing Articles

The Induction of Antigen 85B-Specific CD8 T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice.

Komine-Aizawa S, Mizuno S, Kawano A, Hayakawa S, Matsuo K, Honda M Int J Mol Sci. 2023; 24(2).

PMID: 36674484 PMC: 9862620. DOI: 10.3390/ijms24020966.

Characterization of the Protective Immune Responses Conferred by Recombinant BCG Overexpressing Components of Sec Protein Export System.

Nisa A, Counoupas C, Pinto R, Britton W, Triccas J Vaccines (Basel). 2022; 10(6).

PMID: 35746553 PMC: 9229301. DOI: 10.3390/vaccines10060945.

Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against .

Komine-Aizawa S, Mizuno S, Matsuo K, Namiki T, Hayakawa S, Honda M Vaccines (Basel). 2021; 9(11).

PMID: 34835191 PMC: 8618695. DOI: 10.3390/vaccines9111260.

EXPRESSION OF IMMUNOGLOBULIN, GRANZYME-B AND PERFORIN AGAINST Ag85A AND Ag85B PROTEINS OF MYCOBACTERIUM TUBERCULOSIS IN BALB/C MICE.

Fihiruddin , Artama W, Wibawa T, Mertaniasih N Afr J Infect Dis. 2019; 13(2):13-20.

PMID: 31384722 PMC: 6675963. DOI: 10.21010/ajid.v13i2.2.

MHC-restricted Ag85B-specific CD8 T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice.

Komine-Aizawa S, Jiang J, Mizuno S, Hayakawa S, Matsuo K, Boyd L Eur J Immunol. 2019; 49(9):1399-1414.

PMID: 31135967 PMC: 6722017. DOI: 10.1002/eji.201847988.

References

Kaufmann S . Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol. 2006; 6(9):699-704. DOI: 10.1038/nri1920. View

Autran B . Effects of antiretroviral therapy on immune reconstitution. Antivir Ther. 2005; 4 Suppl 3:3-6. View

Johnson J, Okwera A, Hom D, Mayanja H, Mutuluuza Kityo C, Nsubuga P . Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001; 15(16):2137-47. DOI: 10.1097/00002030-200111090-00009. View

. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19. View

Armitige L, Jagannath C, Wanger A, Norris S . Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun. 2000; 68(2):767-78. PMC: 97204. DOI: 10.1128/IAI.68.2.767-778.2000. View

Doherty T, Olsen A, Weischenfeldt J, Huygen K, DSouza S, Kondratieva T . Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis. 2004; 190(12):2146-53. DOI: 10.1086/425931. View

Launois P, Niang M, de Bruyn J, Sarthou J, Rivier F, Drowart A . The major secreted antigen complex (Ag 85) from Mycobacterium bovis bacille Calmette-Guérin is associated with protective T cells in leprosy: a follow-up study of 45 household contacts. J Infect Dis. 1993; 167(5):1160-7. DOI: 10.1093/infdis/167.5.1160. View

Launois P, Huygen K, de Bruyn J, Ndiaye M, Diouf B, Sarthouj L . T cell response to purified filtrate antigen 85 from Mycobacterium bovis Bacilli Calmette-Guérin (BCG) in leprosy patients. Clin Exp Immunol. 1991; 86(2):286-90. PMC: 1554120. DOI: 10.1111/j.1365-2249.1991.tb05811.x. View

Huygen K, Content J, Denis O, Montgomery D, Yawman A, Deck R . Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 1996; 2(8):893-8. DOI: 10.1038/nm0896-893. View

10.

Lahey T, Matee M, Mtei L, Bakari M, Pallangyo K, von Reyn C . Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis. 2009; 9:21. PMC: 2653493. DOI: 10.1186/1471-2334-9-21. View

11.

Matee M, Lahey T, Vuola J, Mtei L, Cole B, Bakari M . Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis. 2006; 195(1):118-23. PMC: 2871300. DOI: 10.1086/509896. View

12.

Vuola J, Ristola M, Cole B, Jarviluoma A, Tvaroha S, Ronkko T . Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS. 2003; 17(16):2351-5. DOI: 10.1097/00002030-200311070-00010. View

13.

Kamath A, Feng C, MacDonald M, Briscoe H, Britton W . Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun. 1999; 67(4):1702-7. PMC: 96517. DOI: 10.1128/IAI.67.4.1702-1707.1999. View

14.

Quigley M, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH . Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001; 15(2):215-22. DOI: 10.1097/00002030-200101260-00011. View

15.

van Dissel J, Arend S, Prins C, Bang P, Tingskov P, Lingnau K . Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine. 2010; 28(20):3571-81. DOI: 10.1016/j.vaccine.2010.02.094. View

16.

Launois P, DeLeys R, Niang M, Drowart A, Andrien M, Dierckx P . T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun. 1994; 62(9):3679-87. PMC: 303018. DOI: 10.1128/iai.62.9.3679-3687.1994. View

17.

Ronning D, Klabunde T, Besra G, Vissa V, Belisle J, Sacchettini J . Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat Struct Biol. 2000; 7(2):141-6. DOI: 10.1038/72413. View

18.

Baldwin S, Dsouza C, Orme I, Liu M, Huygen K, Denis O . Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis. 2000; 79(4):251-9. DOI: 10.1054/tuld.1998.0196. View

19.

Huygen K, Abramowicz D, Vandenbussche P, Jacobs F, de Bruyn J, Kentos A . Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun. 1992; 60(7):2880-6. PMC: 257249. DOI: 10.1128/iai.60.7.2880-2886.1992. View

20.

Chapman A, Munkanta M, Wilkinson K, Pathan A, Ewer K, Ayles H . Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS. 2002; 16(17):2285-93. DOI: 10.1097/00002030-200211220-00008. View